Premium
Verapamil increases serum alkaline phosphatase in hypertensive patients
Author(s) -
SJÖDÉN G.,
ROSENQVIST M.,
KRIEGHOLM E.,
NORDENSTRÖM J.,
BJÖRKHEM I.
Publication year - 1990
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.1990.tb00242.x
Subject(s) - medicine , verapamil , alkaline phosphatase , endocrinology , cardiology , pharmacology , calcium , biochemistry , enzyme , chemistry
. In rats, verapamil decreases intestinal absorption of calcium, increases serum parathyroid hormone (PTH), and induces osteopenia. In this prospective study, verapamil 80‐120 mg three times daily was given for 2 months to 20 patients with hypertension, and the effects on calcium homeostasis were recorded. This dose of verapamil significantly reduced supine systolic and diastolic blood pressure (±SD) from 158/100 ± 9/8 mmHg to 146/89 ± 14/8 mmHg ( P =0.001). Serum alkaline phosphatase (ALP) increased significantly from 2.77 ± 1.06 μkat l −1 to 3.19 ± 1.22 μkat l −1 ( P =0.004), and isoenzymes of ALP of skeletal origin appeared after verapamil treatment. The excretion of sodium in the urine increased (Na/creatinine ratio 8.95 ± 6.01 before and 13.16 ± 8.26 after verapamil; P =0.04), while the excretion of calcium, phosphate and potassium was not changed. PTH was slightly increased at the end of verapamil treatment (1.09 ± 0.54 vs. 0.98 ± 0.74 μg l −1 ; P =0.07), and s‐1,25(OH) 2 D 3 was also somewhat increased (22.3 ± 14.4 vs. 17.6 ± 4.9 ng l −1 ; P= 0.26). Serum Ca was not affected by verapamil (before verapamil 2.43 ± 0.11 mmol l −1 , after verapamil 2.40 ± 0.12 mmol l −1 ; P =0.28). The increase in serum ALP demonstrates that verapamil affects bone cell metabolism in man. This effect could be secondary to the enhancement of PTH secretion.